Neurostimulation Device for Alzheimers Granted FDA …
WEBJan 25, 2021 · Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status. by Patricia Inacio, PhD January 25, 2021. Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S ...
Last Patient Finishes Alzheimer's Trial Testing AZTherapies’ ALZT …
WEBDec 7, 2020 · The COGNITE trial (NCT02547818) was designed to evaluate ALZT-OP1’s safety and effectiveness in people, ages 55 to 79, with early Alzheimer’s disease. A total of 620 patients were recruited at more than 100 clinical sites clinical sites across the U.S., Canada, Australia, and Europe. At study entry, the patients’ disease stage was ...
September is World Alzheimer’s Month; Sept. 21 is Alzheimer’s Day
WEBSep 6, 2022 · Since 2009, ADI has released a World Alzheimer Report on World Alzheimer’s Day and will again on Sept. 21. The reports, which make recommendations for policy and practice, are sources of information on dementia. For this year, the report will provide a global view of post-diagnosis care models, impediments, and best practices through essays, case studies, and shared global experiences.
Alzheimer's News Today Home | Alzheimer's News Today
WEBFosgonimeton fails to meet goal in Alzheimer’s clinical trial: Data. Fosgonimeton, an investigational medication from Athira Pharma, failed to significantly improve cognitive and daily functioning in adults with mild to moderate Alzheimer’s disease who took part in a Phase 2/3 clinical trial, despite being safe and well tolerated, top-line data show.
Latest Data on Alzheimer's Drug Namenda Confirms Beneficial …
WEBby Alice Melão April 24, 2017. Results from four recent studies confirmed the beneficial clinical effects of Namenda (memantine), an FDA-approved Alzheimer’s therapy, to treat the disease’s behavioral and functional symptoms in people with moderate to severe disease. The studies, sponsored by Allergan, are being presented in poster format ...
Exelon (Rivastigmine) - Alzheimer's News Today
WEBExelon is part of a class of drugs called cholinesterase inhibitors. It acts to reversibly block the function of acetylcholinesterase. By inhibiting this enzyme, it prevents the breakdown of the neurotransmitter acetylcholine and increases its levels in the brain. This can provide a temporary relief for some of the symptoms of AD, by improving ...
How to Support a Friend With Alzheimer’s and Their Family
WEBAug 17, 2020 · The correct response may be to just be there, present in your friend’s mourning and sadness. Respond with a listening ear when your friend needs to vent. You could also find a practical way to get involved to help heal a friend’s heartache. Choose one of the following ideas or come up with a plan that is unique to your friend’s experience ...
Aricept (Donepezil) - Alzheimer's News Today
WEBAricept (donepezil) is an oral medication used to treat the symptoms of dementia caused by Alzheimer’s disease (AD). It is marketed by Eisai in collaboration with Pfizer.. How Aricept works. Aricept is part of a class of drugs called “cholinesterase inhibitors.” It is a reversible inhibitor of an enzyme — a catalyst that can trigger a chemical reaction — called acetylcholinesterase.
Simufilam for Alzheimer's Improves Cognition, Behavior After 6 …
WEBFeb 15, 2021 · Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim data show. “Today’s data once again suggests simufilam could be a transformative, novel therapeutic,” Nadav Friedmann, MD, PhD ...
CT1812 slows cognitive decline in proof-of-concept clinical trial
WEBby Marisa Wexler, MS August 22, 2024. Treatment with CT1812, previously called Elayta, slowed the decline of cognitive function among adults with mild to moderate Alzheimer’s disease in a proof-of-concept clinical trial dubbed SHINE. That’s according to results seen after approximately six months of treatment in the Phase 2 SHINE study ...
Skip to content